Co-Authors
This is a "connection" page, showing publications co-authored by ZIJUN XU-MONETTE and LAN PHAM.
Connection Strength
0.725
-
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
Score: 0.167
-
B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817.
Score: 0.162
-
Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611.
Score: 0.143
-
Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Am J Cancer Res. 2022; 12(10):4666-4679.
Score: 0.054
-
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260.
Score: 0.047
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
Score: 0.047
-
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716.
Score: 0.037
-
RelA NF-?B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016 12 08; 8(12):3321-3340.
Score: 0.036
-
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80.
Score: 0.033